针对IL17A及其受体的aptamers抑制了不同细胞类型的IL17信号传递
Anastasiya Solovieva1, Dariya Rippinen1, Anna Davydova2
1Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of Federal Research Center of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, 630117 Novosibirsk, Russia.
Pharmaceuticals (Basel, Switzerland)
|February 27, 2026
概括
向INTERLEUKIN-17A (IL-17A) 和其受体的寡核酸聚体显示出作为治疗炎症关节病的单克隆抗体的替代品的希望. 在细胞模型中,这些胺酶有效地抑制了IL-17A诱导的炎症,这表明了脊髓关节炎治疗的潜力.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 介素-17A (IL-17A) 是自身免疫性关节病的关键细胞因子.
- 目前的IL-17A抑制剂 (单克隆抗体) 有免疫性和反应丧失等局限性.
研究的目的:
- 评估寡核酸坦体作为抑制IL-17A驱动炎症的单克隆抗体的潜在替代品.
- 在与免疫炎症性类风湿性疾病相关的细胞模型中评估阿帕特默的疗效.
主要方法:
- 对IL-17A进行了2'-F-RNA吸收体 (Apt21-2,Apt3-4) 和对IL-17受体进行了DNA吸收体 (RA10-6) 的测试.
- 在PBMC和来自患者的纤维细胞样同胞细胞 (FLS) 中评估IL-17A功能性活性抑制,来自轴性脊髓关节炎 (axSpA) 和类风湿性关节炎 (RA) 患者.
- 使用ELISA和流式细胞计量测量IL-6和MMP-13的分泌量,使用secukinumab作为对照.
主要成果:
- 阿普塔默在PBMC中抑制了IL-17A刺激的IL-6分泌和扩散 (有效率为65-85%),与secukinumab相似.
- 在axSpA FLS中,阿普坦体表现出时间依赖的疗效;RA10-6保持高疗效时间比Apt21-2和Apt3-4.
- 结合的阿帕特马治疗显示出协同的IL-6抑制;所有阿帕特马都将MMP-13降低到基底水平. 在RA FLS中,反应减少.
结论:
- 阿普塔默在体外抑制IL-17A信号传递方面表现出高特异性和持续有效性,在某些方面表现优于抗体.
- 在RAFLS中差异性疗效突出了疾病异质性,与RA中抗IL-17疗法的临床观察一致.
- 研究的阿普他具有作为IL-17相关炎症性关节病,特别是脊椎关节炎的新疗法药物的显著潜力.
相关概念视频
T Cell Types and Functions
2.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.9K
The JAK-STAT Signaling Pathway
13.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.4K


